Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is an American commercial-stage biopharmaceutical company focused on developing topical dermatological treatments. The company formulates and commercializes topical therapies using its proprietary formulation technology, featuring its lead product Zoryve for plaque psoriasis and seborrheic dermatitis. Principal revenues derive from commercial sales of prescription dermatological creams and foams to pharmaceutical wholesalers and specialty pharmacies. Core end markets encompass dermatology clinics, outpatient medical facilities, and prescription consumers across the United States. Arcutis Biotherapeutics holds a prominent market position as a developer of innovative topical PDE4 inhibitors for inflammatory skin conditions. The company is headquartered in Westlake Village, California, and its common stock trades on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Arcutis Biotherapeutics.
- Legal name
- Arcutis Biotherapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Arcutis Biotherapeutics
- Polar Capital Biotechnology Fund — Polar Capital · 5.2 % (largest positions only, October 2026)
- Arctic Aurora LifeScience — Arctic · 2.9 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 2.88 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.11 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.21 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)